Pioglitazone and barriers to effective post-stroke comorbidity management in stroke survivors with diabetes

References

1. 1.↵
   1. Laakso M

   . Cardiovascular disease in type 2 diabetes from population to man to mechanisms: the Kelly West Award Lecture 2008. Diabetes Care 2010; 33: 442–449.

   OpenUrlFREE Full Text
2. 2.↵
   1. Zhang C,
   2. Zhou YH,
   3. Xu CL,
   4. Chi FL,
   5. Ju HN

   . Efficacy of intensive control of glucose in stroke prevention: a meta-analysis of data from 59197 participants in 9 randomized controlled trials. PLoS One 2013; 8: e54465.

   OpenUrlCrossRefPubMed
3. 3.↵
   1. Dormandy JA,
   2. Charbonnel B,
   3. Eckland DJA,
   4. Erdmann E,
   5. Massi-Benedetti M,
   6. Moules IK, et al.

   Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005; 366: 1279–1289.

   OpenUrlCrossRefPubMedWeb of Science
4. 4.↵
   1. Kernan WN,
   2. Viscoli CM,
   3. Furie KL,
   4. Young LH,
   5. Inzucchi SE,
   6. Gorman M, et al.

   Pioglitazone after ischemic stroke or transient ischemic attack. N Engl J Med 2016; 374: 1321–1331.

   OpenUrlCrossRefPubMed
5. 5.↵
   1. Sandercock PAG,
   2. Gubitz GJ,
   3. Foley P,
   4. Counsell C

   . Antiplatelet therapy for acute ischaemic stroke. Cochrane Database Syst Rev 2008; CD000029.
6. 6.↵
   1. Tramacere I,
   2. Boncoraglio GB,
   3. Banzi R,
   4. Giovane CD,
   5. Kwag KH,
   6. Squizzato A, et al.

   Comparison of statins for secondary prevention in patients with ischemic stroke or transient ischemic attack: a systematic review and network meta-analysis. BMC Med 2019; 17: 67.

   OpenUrlPubMed
7. 7.↵
   1. Kernan WN,
   2. Viscoli CM,
   3. Dearborn JL,
   4. Kent DM,
   5. Conwit R,
   6. Fayad P, et al.

   Targeting pioglitazone hydrochloride therapy after stroke or transient ischemic attack according to pretreatment risk for stroke or myocardial infarction. JAMA Neurol 2017; 74: 1319–1327.

   OpenUrl
8. 8.↵
   1. Young LH,
   2. Viscoli CM,
   3. Schwartz GG,
   4. Inzucchi SE,
   5. Curtis JP,
   6. Gorman MJ, et al.

   Heart failure after ischemic stroke or transient ischemic attack in insulin-resistant patients without diabetes mellitus treated with pioglitazone. Circulation 2018; 138: 1210–1220.

   OpenUrlCrossRef
9. 9.↵
   1. Viscoli CM,
   2. Inzucchi SE,
   3. Young LH,
   4. Insogna KL,
   5. Conwit R,
   6. Furie KL, et al.

   Pioglitazone and risk for bone fracture: safety data from a randomized clinical trial. J Clin Endocrinol Metab 2017; 102: 914–922.

   OpenUrl
10. 10.↵
    1. Dawson J,
    2. Béjot Y,
    3. Christensen LM,
    4. De Marchis GM,
    5. Dichgans M,
    6. Hagberg G, et al.

    European Stroke Organisation (ESO) guideline on pharmacological interventions for long-term secondary prevention after ischaemic stroke or transient ischaemic attack. Eur Stroke J 2022; 7: I–II.

    OpenUrlCrossRefPubMed
11. 11.↵
    1. Glaser BG,
    2. Strauss AL

    , editors. The discovery of grounded theory: strategies for qualitative research. 1st edn. Chicago (USA): Aldine Transaction; 1967.
12. 12.↵
    1. Creswell JW,
    2. Poth CN

    , editors. Qualitative inquiry and research design: choosing among five approaches. 4th edn.SAGE Publications: London (UK); 2017.
13. 13.↵
    1. Foley G,
    2. Timonen V

    . Using grounded theory method to capture and analyze health care experiences. Health Services Research 2014; 50:1195–1210.

    OpenUrl
14. 14.↵
    1. Saldana J

    . The coding manual for qualitative researchers. SAGE Publications: London (UK); 2013.
15. 15.↵
    1. Tong A,
    2. Sainsbury P,
    3. Craig J

    . Consolidated criteria for reporting qualitative research (COREQ): a 32-item checklist for interviews and focus groups. Int J Qual Health Care 2007; 19: 349–357.

    OpenUrlCrossRefPubMedWeb of Science
16. 16.↵
    1. Wan TTH,
    2. Terry A,
    3. McKee B,
    4. Kattan W

    . KMAP-O framework for care management research of patients with type 2 diabetes. World J Diabetes 2017; 8: 165–171.

    OpenUrl
17. 17.↵
    1. Tversky A,
    2. Kahneman D

    . Loss aversion in riskless choice: a reference-dependent model. Q J Econ 1991; 106: 1039–1061.

    OpenUrlCrossRefWeb of Science
18. 18.↵
    1. Miyazaki Y,
    2. Mahankali A,
    3. Matsuda M,
    4. Mahankali S,
    5. Hardies J,
    6. Cusi K, et al.

    Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab 2002; 87: 2784–2791.

    OpenUrlCrossRefPubMedWeb of Science
19. 19.↵
    1. Zanchi A,
    2. Chiolero A,
    3. Maillard M,
    4. Nussberger J,
    5. Brunner HR,
    6. Burnier M

    . Effects of the peroxisomal proliferator-activated receptor-gamma agonist pioglitazone on renal and hormonal responses to salt in healthy men. J Clin Endocrinol Metab 2004; 89: 1140–1145.

    OpenUrlCrossRefPubMedWeb of Science
20. 20.↵
    1. Young LH,
    2. Viscoli CM,
    3. Curtis JP,
    4. Inzucchi SE,
    5. Schwartz GG,
    6. Lovejoy AM, et al.

    Cardiac outcomes after ischemic stroke or transient ischemic attack: effects of pioglitazone in patients with insulin resistance without diabetes mellitus. Circulation 2017; 135: 1882–1893.

    OpenUrlAbstract/FREE Full Text
21. 21.↵
    1. Erdmann E,
    2. Charbonnel B,
    3. Wilcox RG,
    4. Skene AM,
    5. Massi-Benedetti M,
    6. Yates J, et al.

    Pioglitazone use and heart failure in patients with type 2 diabetes and preexisting cardiovascular disease: data from the PROactive study (PROactive 08). Diabetes Care 2007; 30: 2773–2778.

    OpenUrlAbstract/FREE Full Text
22. 22.↵
    1. Roberts E,
    2. Ludman AJ,
    3. Dworzynski K,
    4. Al-Mohammad A,
    5. Cowie MR,
    6. McMurray JJV, et al.

    The diagnostic accuracy of the natriuretic peptides in heart failure: systematic review and diagnostic meta-analysis in the acute care setting. BMJ 2015; 350: h910.

    OpenUrlAbstract/FREE Full Text
23. 23.↵
    1. Gupta AK,
    2. Smith SR,
    3. Greenway FL,
    4. Bray GA

    . Pioglitazone treatment in type 2 diabetes mellitus when combined with portion control diet modifies the metabolic syndrome. Diabetes Obes Metab 2009; 11: 330–337.

    OpenUrlCrossRefPubMed
24. 24.↵
    1. Shadid S,
    2. Jensen MD

    . Effects of pioglitazone versus diet and exercise on metabolic health and fat distribution in upper body obesity. Diabetes Care 2003; 26: 3148–3152.

    OpenUrlAbstract/FREE Full Text
25. 25.↵
    1. Wei W,
    2. Zeve D,
    3. Wang X,
    4. Du Y,
    5. Tang W,
    6. Dechow PC, et al.

    Osteoclast progenitors reside in the peroxisome proliferator-activated receptor γ-expressing bone marrow cell population. Mol Cell Biol 2011; 31: 4692–4705.

    OpenUrlAbstract/FREE Full Text
26. 26.↵
    1. Dormandy J,
    2. Bhattacharya M,
    3. van Troostenburg de Bruyn A

    ; PROactive investigators. Safety and tolerability of pioglitazone in high-risk patients with type 2 diabetes: an overview of data from PROactive. Drug Saf 2009; 32: 187–202.

    OpenUrlCrossRefPubMedWeb of Science
27. 27.↵
    1. Jiang X,
    2. Gruner M,
    3. Trémollieres F,
    4. Pluskiewicz W,
    5. Sornay-Rendu E,
    6. Adamczyk P, et al.

    Diagnostic accuracy of FRAX in predicting the 10-year risk of osteoporotic fractures using the USA treatment thresholds: a systematic review and meta-analysis. Bone 2017; 99: 20–25.

    OpenUrl
28. 28.↵
    1. Kanis J,
    2. Oden A,
    3. Johnell O

    . Acute and long-term increase in fracture risk after hospitalization for stroke. Stroke 2001; 32: 702–706.

    OpenUrlAbstract/FREE Full Text
29. 29.↵
    1. McCloskey EV,
    2. Odén A,
    3. Harvey NC,
    4. Leslie WD,
    5. Hans D,
    6. Johansson H, et al.

    A meta-analysis of trabecular bone score in fracture risk prediction and its relationship to FRAX. J Bone Miner Res 2016; 31: 940–948.

    OpenUrlCrossRefPubMed
30. 30.↵
    1. Gupta A,
    2. Prabhakar S,
    3. Modi M,
    4. Bhadada SK,
    5. Kalaivani M,
    6. Lal V, et al.

    Effect of vitamin D and calcium supplementation on ischaemic stroke outcome: a randomised controlled open-label trial. Int J Clin Pract 2016; 70: 764–770.

    OpenUrl
31. 31.↵
    1. Poole KES,
    2. Reeve J,
    3. Warburton EA. Falls

    , fractures, and osteoporosis after stroke time to think about protection? Stroke 2002; 33: 1432–1436.

    OpenUrlAbstract/FREE Full Text
32. 32.↵
    European Stroke Organisation (ESO) Executive Committee, ESO Writing Committee. Guidelines for management of ischaemic stroke and transient ischaemic attack 2008. Cerebrovasc Dis 2008; 25: 457–507.

    OpenUrlCrossRefPubMedWeb of Science
33. 33.↵
    1. Kleindorfer DO,
    2. Towfighi A,
    3. Chaturvedi S,
    4. Cockroft KM,
    5. Gutierrez G,
    6. Lombardi-Hill D, et al.

    2021 guideline for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline from the American Heart Association/American Stroke Association. Stroke 2021; 52: e364–e467.

    OpenUrlCrossRefPubMed
34. 34.↵
    1. Craig P,
    2. Dieppe P,
    3. Macintyre S,
    4. Michie S,
    5. Nazareth I,
    6. Petticrew M

    . Developing and evaluating complex interventions: the new Medical Research Council guidance. BMJ 2008; 337: a1655.

    OpenUrlFREE Full Text
35. 35.↵
    1. Davidoff F

    . Can knowledge about heterogeneity in treatment effects help us choose wisely? Ann Intern Med 2016; 166: 141–142.

    OpenUrl
36. 36.↵
    1. Batchelor FA,
    2. Mackintosh SF,
    3. Said CM,
    4. Hill KD

    . Falls after stroke. Int J Stroke 2012; 7: 482–490.

    OpenUrlCrossRefPubMedWeb of Science
37. 37.↵
    1. Luengo-Fernández R,
    2. Leal J,
    3. Gray A,
    4. Petersen S,
    5. Rayner M

    . Cost of cardiovascular diseases in the United Kingdom. Heart 2006; 92: 1384–1389.

    OpenUrlAbstract/FREE Full Text
38. 38.↵
    1. Say RE,
    2. Thomson R

    . The importance of patient preferences in treatment decisions--challenges for doctors. BMJ 2003; 327: 542–545.

    OpenUrlFREE Full Text
39. 39.↵
    1. Sekhon M,
    2. Cartwright M,
    3. Francis JJ

    . Acceptability of healthcare interventions: an overview of reviews and development of a theoretical framework. BMC Health Serv Res 2017; 17: 88.

    OpenUrlCrossRefPubMed
40. 40.↵
    1. Mason M

    . Sample size and saturation in PhD studies using qualitative interviews. Forum Qual Soc Res 2010; 11: Art. 8.

    OpenUrl